222 related articles for article (PubMed ID: 34125296)
1. Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan.
Soen S; Kaku M; Okubo N; Touzeni S; Saito K; Kobayashi M
J Bone Miner Metab; 2021 Nov; 39(6):1019-1030. PubMed ID: 34125296
[TBL] [Abstract][Full Text] [Related]
2. Fracture risk associated with glucocorticoid-induced osteoporosis in Japan.
Soen S; Kaku M; Okubo N; Onishi Y; Saito K; Kobayashi M
J Bone Miner Metab; 2022 Jul; 40(4):636-647. PubMed ID: 35546370
[TBL] [Abstract][Full Text] [Related]
3. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
Hayakawa N; Suzuki A
Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
[TBL] [Abstract][Full Text] [Related]
4. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis.
Abdullah H; Koller G; Zuna I; Yuksel N; Charrois T; Mandhane R; Cotton K; Danilak M; Bell H; Ye C
Arch Osteoporos; 2021 Jul; 16(1):108. PubMed ID: 34347188
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
[TBL] [Abstract][Full Text] [Related]
7. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.
Feldstein AC; Elmer PJ; Nichols GA; Herson M
Osteoporos Int; 2005 Dec; 16(12):2168-74. PubMed ID: 16142501
[TBL] [Abstract][Full Text] [Related]
8. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.
Gourlay M; Franceschini N; Sheyn Y
Clin Rheumatol; 2007 Feb; 26(2):144-53. PubMed ID: 16670825
[TBL] [Abstract][Full Text] [Related]
9. Status of Glucocorticoid-Induced Osteoporosis Preventive Care in Korea: A Retrospective Cohort Study on the Korean National Health Insurance Service Database.
Song BW; Kim AR; Kim MA; Kim HS; Lee SG
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208647
[No Abstract] [Full Text] [Related]
10. Glucocorticoid-induced osteoporosis: 2019 concise clinical review.
Adami G; Saag KG
Osteoporos Int; 2019 Jun; 30(6):1145-1156. PubMed ID: 30805679
[TBL] [Abstract][Full Text] [Related]
11. Management of glucocorticoid-induced osteoporosis.
Rizzoli R; Adachi JD; Cooper C; Dere W; Devogelaer JP; Diez-Perez A; Kanis JA; Laslop A; Mitlak B; Papapoulos S; Ralston S; Reiter S; Werhya G; Reginster JY
Calcif Tissue Int; 2012 Oct; 91(4):225-43. PubMed ID: 22878667
[TBL] [Abstract][Full Text] [Related]
12. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.
Yu SF; Chen JF; Chen YC; Lai HM; Ko CH; Chiu WC; Su FM; Hsu CY; Su BY; Wu CH; Cheng TT
Medicine (Baltimore); 2017 Feb; 96(5):e5959. PubMed ID: 28151883
[TBL] [Abstract][Full Text] [Related]
13. When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis.
Hayes KN; Baschant U; Hauser B; Burden AM; Winter EM
Front Endocrinol (Lausanne); 2021; 12():782118. PubMed ID: 34975756
[TBL] [Abstract][Full Text] [Related]
14. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
15. Guideline-based Treatment of Glucocorticoid-induced Osteoporosis in Patients with Rheumatoid Arthritis: A Retrospective Study with the AORA Registry.
Kawano T; Miyakoshi N; Tsuchie H; Kashiwagura T; Kobayashi M; Aonuma H; Sugimura Y; Shimada Y
Acta Med Okayama; 2021 Dec; 75(6):699-704. PubMed ID: 34955537
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid-induced osteoporosis preventive care in rheumatology patients.
Koller G; Katz S; Charrois TL; Ye C
Arch Osteoporos; 2019 Feb; 14(1):16. PubMed ID: 30723883
[TBL] [Abstract][Full Text] [Related]
17. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008).
Majumdar SR; Lix LM; Yogendran M; Morin SN; Metge CJ; Leslie WD
J Clin Endocrinol Metab; 2012 Apr; 97(4):1236-42. PubMed ID: 22298803
[TBL] [Abstract][Full Text] [Related]
18. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first.
Lespessailles E; Chapurlat R
Osteoporos Int; 2020 Oct; 31(10):1829-1834. PubMed ID: 32780152
[TBL] [Abstract][Full Text] [Related]
19. Barriers in the management of glucocorticoid-induced osteoporosis.
Guzman-Clark JR; Fang MA; Sehl ME; Traylor L; Hahn TJ
Arthritis Rheum; 2007 Feb; 57(1):140-6. PubMed ID: 17266078
[TBL] [Abstract][Full Text] [Related]
20. Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
Osteoporos Int; 2022 May; 33(5):1097-1108. PubMed ID: 35022812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
